沙美特罗氟替卡松粉吸入剂联合阿奇霉素治疗肺炎支原体感染的疗效观察

Observation on Efficacy of Salmeterol and Fluticasone Powder for Inhalation Combined with Azithromycin in Treatment of Mycoplasma Pneumoniae Infection

目的:探讨沙美特罗氟替卡松粉吸入剂联合阿奇霉素治疗肺炎支原体感染的临床疗效。方法:选取2014年8月至2018年4月荆州市胸科医院收治的肺炎支原体感染患者200例,采用随机数字表法分为对照组和观察组,每组100例。对照组患者给予阿奇霉素治疗,观察组患者在对照组的基础上加用沙美特罗氟替卡松粉吸入剂治疗。比较两组患者的临床疗效、肺功能指标水平[1 s用力呼气容积(FEV_1)、1 s用力呼气容积占用力肺活量百分比(FEV_1/FVC)及呼气峰流速(PEF)]、临床症状和体征改善情况及不良反应发生情况的差异。结果:观察组患者的总有效率为88.00%(88/100),明显高于对照组的65.00%(65/100),差异有统计学意义(P<0.05);治疗后,观察组患者的FEV_1、FEV_1/FVC及PEF水平明显高于治疗前和对照组治疗后,差异均有统计学意义(P<0.05);治疗后,观察组患者的肺部啰音消失时间、喘憋缓解时间和咳嗽缓解时间明显短于对照组,差异均有统计学意义(P<0.05);观察组、对照组患者不良反应发生率分别为2.00%(2/100)、4.00%(4/100),差异无统计学意义(P>0.05)。结论:沙美特罗氟替卡松粉吸入剂联合阿奇霉素治疗肺炎支原体感染的疗效显著,能够有效改善患者的肺功能和临床症状。

OBJECTIVE: To probe into the efficacy of salmeterol and fluticasone powder for inhalation combined with azithromycin in treatment of mycoplasma pneumoniae infection. METHODS: 200 patients with mycoplasma pneumoniae infection admitted into Jingzhou Chest Hospital from Aug. 2014 to Apr. 2018 were selected and divided into control group and observation group via random number table, with 100 cases in each group. The control group was treated with azithromycin, while the observation group was given salmeterol and fluticasone powder for inhalation based on the control group. Differences in clinical efficacy, pulmonary function indices [forced expiratory volume in 1 s(FEV1), percentage of FEV1 accounted for forced vital capacity(FEV1/FVC) and peak expiratory flow(PEF)], improvements of clinical symptoms and signs, incidences of adverse drug reactions between two groups were compared. RESULTS: The total effective rate of observation group was 88.00%(88/100), which was significantly higher than that of the control group(65.00%, 65/100), with statistically significant difference(P<0.05);after treatment, the FEV1, FEV1/FVC and PEF of observation group was significantly higher than those of before treatment and the control group, with statistically significant differences(P<0.05);after treatment, the disappearance times of lung rale, remission time of asthma and cough of observation group were significantly shorter than those of the control group, with statistically significant differences(P<0.05);the incidences of adverse drug reactions of observation group and control group were respectively 2.00%(2/100) and 4.00%(4/100), the difference had no statistical significance(P>0.05). CONCLUSIONS: The efficacy of salmeterol and fluticasone powder for inhalation combined with azithromycin in treatment of mycoplasma pneumoniae infection is remarkable, which can effectively improve patients’ pulmonary function and clinical signs.